U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Spectrum Laboratory Products, Inc. - 573311 - 06/24/2021
  1. Warning Letters

CLOSEOUT LETTER

Spectrum Laboratory Products, Inc. MARCS-CMS 573311 —

Delivery Method:
Via Email Delivery Confirmation
Product:
Drugs
Recipient:
Recipient Name
Russell Kneipp
Recipient Title
Chief Operating Officer
Spectrum Laboratory Products, Inc.

14422 S. San Pedro Street
Gardena, CA 90248-2027
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

Dear Mr. Kneipp:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter [CMS #573311 and dated June 4, 2019]. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top